Population PK / PD Modeling for Evaluation of Intertwining Effects of Drug and Disease on Thrombocytopenia in Acute Leukemias

In hematological malignancies, thrombocytopenia is a frequent feature of the disease. Anti-leukemic therapies are known to impact thrombocytopenia, which is commonly selected as a dose-limiting toxicity in early clinical trials. However, given the concurrent myelosuppressive effects of the drug and the underlying leukemia, it can be difficult to differentiate whether the dose of the investigational treatment should be decreased to manage thrombocytopenia or, on the contrary, increased in pursuit